Ignite Creation Date:
2025-12-24 @ 11:48 PM
Ignite Modification Date:
2026-02-06 @ 8:33 PM
Study NCT ID:
NCT00649051
Status:
COMPLETED
Last Update Posted:
2024-04-24
First Post:
2008-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg
Sponsor:
Mylan Pharmaceuticals Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
METO-02110
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Will Sullvan, Global Head of Product Risk and Safety Management
Old Organization:
Mylan Inc.